Bio-Techne (TECH)
Bio-Techne on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
7.6M
Short interest
settlement 2026-10-15
2.9
Days to cover
+0.8 days vs prior
35.2%
Short share of volume
2026-10-28
48,379
Fails to deliver
settlement 2026-09-22
Wed 4 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in TECH is 7,552,208 shares, up 924,585 shares over the last month. Over the last 48 readings it ranged from 3,173,267 shares (31 October 2024) to 18,204,307 shares (15 June 2026). At the reported average volume of 2.6M shares a day that is 2.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/tech" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 7,552,208 | +2.3% | 2,624,542 | 2.88 |
| 2026-09-30 | 7,385,034 | +11.4% | 3,556,189 | 2.08 |
| 2026-09-15 | 6,627,623 | +12.5% | 2,492,188 | 2.66 |
| 2026-08-31 | 5,889,876 | -8.9% | 2,359,300 | 2.50 |
| 2026-08-14 | 6,463,327 | -30.3% | 2,850,913 | 2.27 |
| 2026-07-31 | 9,277,342 | -23.5% | 3,964,369 | 2.34 |
| 2026-07-15 | 12,123,448 | -23.8% | 5,339,634 | 2.27 |
| 2026-06-30 | 15,915,631 | -12.6% | 10,806,094 | 1.47 |
| 2026-06-15 | 18,204,307 | +31.5% | 2,955,086 | 6.16 |
| 2026-05-29 | 13,846,089 | -4.9% | 2,788,250 | 4.97 |
| 2026-05-15 | 14,553,011 | +9.1% | 3,959,564 | 3.68 |
| 2026-04-30 | 13,338,470 | -4.7% | 1,997,784 | 6.68 |
| 2026-04-15 | 14,001,926 | -0.7% | 1,965,228 | 7.12 |
| 2026-03-31 | 14,099,778 | +14.1% | 2,118,068 | 6.66 |
| 2026-03-13 | 12,352,658 | +16.8% | 2,485,940 | 4.97 |
| 2026-02-27 | 10,579,001 | -6.5% | 2,150,126 | 4.92 |
| 2026-02-13 | 11,308,392 | +14.9% | 2,872,427 | 3.94 |
| 2026-01-30 | 9,838,546 | -5.0% | 2,358,971 | 4.17 |
| 2026-01-15 | 10,356,637 | +3.1% | 2,301,455 | 4.50 |
| 2025-12-31 | 10,044,054 | +6.7% | 1,399,718 | 7.18 |
| 2025-12-15 | 9,414,943 | +1.8% | 1,778,286 | 5.29 |
| 2025-11-28 | 9,250,239 | -0.2% | 1,706,315 | 5.42 |
| 2025-11-14 | 9,265,811 | +22.1% | 2,402,060 | 3.86 |
| 2025-10-31 | 7,588,721 | +9.4% | 1,756,448 | 4.32 |
| 2025-10-15 | 6,939,394 | +28.9% | 2,682,825 | 2.59 |
| 2025-09-30 | 5,384,729 | +2.1% | 2,681,022 | 2.01 |
| 2025-09-15 | 5,273,911 | +2.9% | 2,155,931 | 2.45 |
| 2025-08-29 | 5,124,437 | -11.2% | 1,946,496 | 2.63 |
| 2025-08-15 | 5,772,492 | -8.9% | 2,390,564 | 2.41 |
| 2025-07-31 | 6,335,952 | -3.0% | 2,298,887 | 2.76 |
| 2025-07-15 | 6,530,665 | +3.4% | 1,680,468 | 3.89 |
| 2025-06-30 | 6,315,794 | +2.9% | 2,196,122 | 2.88 |
| 2025-06-13 | 6,139,163 | -18.5% | 2,171,150 | 2.83 |
| 2025-05-30 | 7,536,792 | +4.6% | 2,912,321 | 2.59 |
| 2025-05-15 | 7,203,941 | +11.2% | 2,713,102 | 2.66 |
| 2025-04-30 | 6,480,598 | +0.4% | 1,887,474 | 3.43 |
| 2025-04-15 | 6,457,278 | +6.7% | 2,558,849 | 2.52 |
| 2025-03-31 | 6,050,312 | -3.4% | 1,519,879 | 3.98 |
| 2025-03-14 | 6,265,697 | +18.9% | 2,397,191 | 2.61 |
| 2025-02-28 | 5,269,076 | +3.8% | 1,662,592 | 3.17 |
| 2025-02-14 | 5,076,499 | +28.6% | 1,907,771 | 2.66 |
| 2025-01-31 | 3,948,474 | -2.5% | 1,047,329 | 3.77 |
| 2025-01-15 | 4,051,390 | +7.3% | 818,917 | 4.95 |
| 2024-12-31 | 3,774,113 | +7.5% | 696,292 | 5.42 |
| 2024-12-13 | 3,509,200 | -14.0% | 679,873 | 5.16 |
| 2024-11-29 | 4,079,004 | +15.7% | 1,111,537 | 3.67 |
| 2024-11-15 | 3,525,556 | +11.1% | 1,002,883 | 3.52 |
| 2024-10-31 | 3,173,267 | -11.9% | 1,054,530 | 3.01 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of TECH volume is 35.2%, down 18.6 points over the last five sessions. Over the last 30 readings it ranged from 9.7% (21 September 2026) to 58.4% (23 October 2026). The latest reading is in line with the 30-session average of 36.3%, on 720K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 253K | 720K | 35.2% | 408 |
| 2026-10-27 | 362K | 935K | 38.7% | 513 |
| 2026-10-26 | 227K | 440K | 51.7% | 196 |
| 2026-10-23 | 323K | 553K | 58.4% | 157 |
| 2026-10-22 | 547K | 1.1M | 48.3% | 341 |
| 2026-10-21 | 479K | 890K | 53.8% | 388 |
| 2026-10-20 | 398K | 932K | 42.7% | 1,414 |
| 2026-10-19 | 480K | 882K | 54.4% | 1,233 |
| 2026-10-16 | 258K | 788K | 32.8% | 3,554 |
| 2026-10-15 | 267K | 977K | 27.3% | 90 |
| 2026-10-14 | 203K | 534K | 38.0% | 1,074 |
| 2026-10-13 | 448K | 806K | 55.5% | 582 |
| 2026-10-12 | 417K | 780K | 53.5% | 0 |
| 2026-10-09 | 179K | 527K | 34.0% | 20 |
| 2026-10-08 | 883K | 2.9M | 30.9% | 752 |
| 2026-10-07 | 325K | 808K | 40.2% | 0 |
| 2026-10-06 | 503K | 1.1M | 45.9% | 3,899 |
| 2026-10-05 | 230K | 589K | 39.1% | 0 |
| 2026-10-02 | 198K | 617K | 32.1% | 54 |
| 2026-10-01 | 381K | 958K | 39.8% | 213 |
| 2026-09-30 | 285K | 604K | 47.2% | 69 |
| 2026-09-29 | 325K | 931K | 34.9% | 0 |
| 2026-09-28 | 156K | 1.2M | 12.6% | 2,810 |
| 2026-09-25 | 154K | 588K | 26.3% | 0 |
| 2026-09-24 | 89K | 844K | 10.6% | 33 |
| 2026-09-23 | 324K | 1.5M | 21.5% | 400 |
| 2026-09-22 | 170K | 1.4M | 12.5% | 20,937 |
| 2026-09-21 | 125K | 1.3M | 9.7% | 68 |
| 2026-09-18 | 629K | 1.2M | 52.1% | 1,097 |
| 2026-09-17 | 200K | 1.9M | 10.7% | 33 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 22 September 2026, the fails-to-deliver balance in TECH is 48,379 shares, up 47,278 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (10 June 2026) to 252,963 shares (30 June 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-22 | 48,379 | $72.47 | $3.5M |
| 2026-09-21 | 1,101 | $72.37 | $80K |
| 2026-09-18 | 2,696 | $72.41 | $195K |
| 2026-09-14 | 33 | $72.12 | $2K |
| 2026-09-04 | 38 | $72.45 | $3K |
| 2026-09-02 | 23 | $72.18 | $2K |
| 2026-08-31 | 185 | $72.35 | $13K |
| 2026-08-28 | 1,028 | $72.47 | $74K |
| 2026-08-27 | 1,850 | $72.38 | $134K |
| 2026-08-24 | 5,542 | $72.32 | $401K |
| 2026-08-19 | 29 | $72.22 | $2K |
| 2026-08-17 | 190 | $72.40 | $14K |
| 2026-08-11 | 8,190 | $72.12 | $591K |
| 2026-08-05 | 1,857 | $72.09 | $134K |
| 2026-08-04 | 14,608 | $72.14 | $1.1M |
| 2026-08-03 | 1,562 | $72.09 | $113K |
| 2026-07-22 | 98 | $71.63 | $7K |
| 2026-06-30 | 252,963 | $70.90 | $17.9M |
| 2026-06-29 | 63,201 | $71.00 | $4.5M |
| 2026-06-26 | 69,386 | $70.70 | $4.9M |
| 2026-06-25 | 49,705 | $58.88 | $2.9M |
| 2026-06-24 | 273 | $56.26 | $15K |
| 2026-06-18 | 97 | $55.00 | $5K |
| 2026-06-16 | 2 | $56.17 | $112 |
| 2026-06-15 | 1,406 | $54.00 | $76K |
| 2026-06-12 | 6,534 | $54.02 | $353K |
| 2026-06-11 | 36,081 | $52.50 | $1.9M |
| 2026-06-10 | 1 | $54.41 | $54 |
| 2026-06-09 | 662 | $52.65 | $35K |
| 2026-06-05 | 29,623 | $53.18 | $1.6M |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for TECH in the last 90 days. The most recent filings are listed below. Latest filing: HIGGINS JOHN L (Director) on 2026-09-28.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-28 | HIGGINS JOHN L | Director | Tax withholding | 6K | $72.51 | $403K | 77K |
| 2026-09-28 | HIGGINS JOHN L | Director | Exercise or conversion | 16K | $0.00 | $0 | 83K |
| 2026-09-22 | BAUMGARTNER ROBERT V | Director | Tax withholding | 6K | $72.55 | $403K | 57K |
| 2026-09-22 | BAUMGARTNER ROBERT V | Director | Exercise or conversion | 16K | $0.00 | $0 | 62K |
| 2026-08-15 | Kelderman Kim | Chief Executive Officer | Tax withholding | 11K | $72.40 | $783K | 83K |
| 2026-08-15 | Kelderman Kim | Chief Executive Officer | Exercise or conversion | 21K | $0.00 | $0 | 94K |
| 2026-08-15 | Hippel James | CFO | Tax withholding | 4K | $72.40 | $312K | 170K |
| 2026-08-15 | Hippel James | CFO | Exercise or conversion | 10K | $0.00 | $0 | 174K |
| 2026-08-15 | Geist William | PRESIDENT, PROTEIN SCIENCES | Tax withholding | 2K | $72.40 | $143K | 25K |
| 2026-08-15 | Geist William | PRESIDENT, PROTEIN SCIENCES | Exercise or conversion | 6K | $0.00 | $0 | 27K |
| 2026-08-15 | Bohnen Shane | SVP - General Counsel | Tax withholding | 1K | $72.40 | $97K | 10K |
| 2026-08-15 | Bohnen Shane | SVP - General Counsel | Exercise or conversion | 4K | $0.00 | $0 | 12K |
| 2026-08-15 | Crouse Steven C. | President - Diag & Spatial Bi | Tax withholding | 2K | $72.40 | $141K | 10K |
| 2026-08-15 | Crouse Steven C. | President - Diag & Spatial Bi | Exercise or conversion | 5K | $0.00 | $0 | 12K |
| 2026-08-15 | Herr Amy E. | Director | Tax withholding | 213 | $72.40 | $15K | 576 |
| 2026-08-15 | Herr Amy E. | Director | Exercise or conversion | 589 | $0.00 | $0 | 789 |
| 2026-07-29 | Hippel James | CFO | Tax withholding | 51K | $72.03 | $3.7M | 165K |
| 2026-07-29 | Hippel James | CFO | Exercise or conversion | 62K | $47.60 | $3.0M | 216K |
| 2026-07-28 | Kelderman Kim | Chief Executive Officer | Tax withholding | 29K | $72.07 | $2.1M | 72K |
| 2026-07-28 | Kelderman Kim | Chief Executive Officer | Exercise or conversion | 35K | $47.60 | $1.7M | 101K |
| 2026-07-23 | Bohnen Shane | SVP - General Counsel | Tax withholding | 344 | $71.77 | $25K | 7K |
| 2026-07-23 | Bohnen Shane | SVP - General Counsel | Exercise or conversion | 448 | $47.60 | $21K | 8K |
| 2026-06-02 | Crouse Steven C. | President - Diag & Spatial Bi | Tax withholding | 216 | $49.77 | $11K | 7K |
| 2026-06-02 | Crouse Steven C. | President - Diag & Spatial Bi | Exercise or conversion | 600 | price not stated in the filing | not stated | 7K |
| 2026-05-08 | Herr Amy E. | Director | Sell | 7K | $48.28 | $320K | 200 |
| 2026-05-08 | Herr Amy E. | Director | Exercise or conversion | 7K | $47.60 | $316K | 7K |
| 2026-05-05 | Hippel James | CFO | Tax withholding | 57K | $56.68 | $3.2M | 154K |
| 2026-05-05 | Hippel James | CFO | Exercise or conversion | 62K | $47.60 | $3.0M | 211K |
| 2026-05-05 | Bohnen Shane | SVP - General Counsel | Tax withholding | 7K | $56.68 | $400K | 7K |
| 2026-05-05 | Bohnen Shane | SVP - General Counsel | Exercise or conversion | 8K | $47.60 | $400K | 14K |
| 2026-05-05 | Kelderman Kim | Chief Executive Officer | Tax withholding | 24K | $56.68 | $1.4M | 66K |
| 2026-05-05 | Kelderman Kim | Chief Executive Officer | Exercise or conversion | 27K | $47.60 | $1.3M | 90K |
| 2026-05-01 | Crouse Steven C. | President - Diag & Spatial Bi | Tax withholding | 311 | $55.02 | $17K | 6K |
| 2026-05-01 | Crouse Steven C. | President - Diag & Spatial Bi | Exercise or conversion | 794 | price not stated in the filing | not stated | 7K |
| 2026-04-22 | Kelderman Kim | Chief Executive Officer | Tax withholding | 1K | $58.58 | $80K | 63K |
| 2026-04-22 | Kelderman Kim | Chief Executive Officer | Exercise or conversion | 11K | $0.00 | $0 | 64K |
| 2026-04-22 | Hippel James | CFO | Tax withholding | 56K | $58.58 | $3.3M | 149K |
| 2026-04-22 | Hippel James | CFO | Exercise or conversion | 62K | $0.00 | $0 | 205K |
| 2026-04-14 | Kelderman Kim | Chief Executive Officer | Tax withholding | 32K | $58.66 | $1.9M | 53K |
| 2026-04-14 | Kelderman Kim | Chief Executive Officer | Exercise or conversion | 37K | $0.00 | $0 | 85K |
| 2026-04-03 | Bohnen Shane | SVP - General Counsel | Tax withholding | 740 | $53.13 | $39K | 6K |
| 2026-04-03 | Bohnen Shane | SVP - General Counsel | Exercise or conversion | 2K | $0.00 | $0 | 7K |
| 2026-02-17 | Herr Amy E. | Director | Sell | 2K | $59.10 | $117K | 200 |
| 2026-02-03 | Herr Amy E. | Director | Tax withholding | 16 | $64.63 | $1K | 2K |
| 2026-02-03 | Herr Amy E. | Director | Exercise or conversion | 38 | $0.00 | $0 | 2K |
| 2026-02-01 | McManus Matthew | President - Diag & Spatial Bio | Tax withholding | 2K | $64.09 | $107K | 8K |
| 2026-02-01 | McManus Matthew | President - Diag & Spatial Bio | Exercise or conversion | 5K | $0.00 | $0 | 9K |
| 2025-11-03 | Kelderman Kim | Chief Executive Officer | Tax withholding | 2K | $62.57 | $144K | 49K |
| 2025-11-03 | Hippel James | CFO | Tax withholding | 12K | $62.57 | $742K | 143K |
| 2025-11-03 | Hippel James | CFO | Exercise or conversion | 12K | $0.00 | $0 | 155K |
| 2025-11-03 | Hippel James | CFO | Exercise or conversion | 13K | $0.00 | $0 | 143K |
| 2025-11-03 | Geist William | PRESIDENT, PROTEIN SCIENCES | Tax withholding | 5K | $62.57 | $283K | 21K |
| 2025-11-03 | Geist William | PRESIDENT, PROTEIN SCIENCES | Exercise or conversion | 10K | $0.00 | $0 | 25K |
| 2025-10-30 | Bushman Julie L | Director | Grant | 2K | $0.00 | $0 | 9K |
| 2025-10-30 | KEEGAN JOSEPH D | Director | Grant | 2K | $0.00 | $0 | 15K |
| 2025-10-30 | HIGGINS JOHN L | Director | Grant | 2K | $0.00 | $0 | 67K |
| 2025-10-30 | Seth Alpna | Director | Grant | 2K | $0.00 | $0 | 15K |
| 2025-10-30 | Herr Amy E. | Director | Grant | 2K | $0.00 | $0 | 3K |
| 2025-10-30 | Klimovsky Judith V. | Director | Grant | 2K | $0.00 | $0 | 4K |
| 2025-10-30 | Vessey Rupert | Director | Grant | 2K | $0.00 | $0 | 11K |
| 2025-10-30 | BAUMGARTNER ROBERT V | Director | Grant | 2K | $0.00 | $0 | 47K |
| 2025-08-25 | Nusse Roeland | Director | Sell | 17K | $56.36 | $960K | 45K |
| 2025-08-25 | Nusse Roeland | Director | Exercise or conversion | 17K | $21.84 | $372K | 62K |
| 2025-08-25 | BAUMGARTNER ROBERT V | Director | Sell | 17K | $56.21 | $958K | 45K |
| 2025-08-25 | BAUMGARTNER ROBERT V | Director | Exercise or conversion | 17K | $21.84 | $372K | 62K |
| 2025-08-15 | Hippel James | CFO | Tax withholding | 2K | $53.60 | $103K | 130K |
| 2025-08-15 | Hippel James | CFO | Exercise or conversion | 4K | $0.00 | $0 | 132K |
| 2025-08-15 | Herr Amy E. | Director | Tax withholding | 101 | $53.60 | $5K | 2K |
| 2025-08-15 | Herr Amy E. | Director | Exercise or conversion | 279 | $0.00 | $0 | 2K |
| 2025-08-15 | Kelderman Kim | Chief Executive Officer | Tax withholding | 4K | $53.60 | $231K | 51K |
| 2025-08-15 | Kelderman Kim | Chief Executive Officer | Exercise or conversion | 9K | $0.00 | $0 | 55K |
| 2025-08-15 | Bohnen Shane | SVP - General Counsel | Tax withholding | 527 | $53.60 | $28K | 4K |
| 2025-08-15 | Bohnen Shane | SVP - General Counsel | Exercise or conversion | 2K | $0.00 | $0 | 5K |
| 2025-08-15 | McManus Matthew | President - Diag & Spatial Bio | Tax withholding | 880 | $53.60 | $47K | 5K |
| 2025-08-15 | McManus Matthew | President - Diag & Spatial Bio | Exercise or conversion | 3K | $0.00 | $0 | 6K |
| 2025-08-15 | Geist William | PRESIDENT, PROTEIN SCIENCES | Tax withholding | 803 | $53.60 | $43K | 15K |
| 2025-08-15 | Geist William | PRESIDENT, PROTEIN SCIENCES | Exercise or conversion | 3K | $0.00 | $0 | 16K |
| 2025-08-07 | HIGGINS JOHN L | Director | Exercise or conversion | 5K | $21.84 | $110K | 65K |
| 2025-07-29 | Hippel James | CFO | Tax withholding | 147K | $58.55 | $8.6M | 128K |
| 2025-07-29 | Hippel James | CFO | Exercise or conversion | 169K | $44.33 | $7.5M | 275K |
| 2025-07-22 | Kelderman Kim | Chief Executive Officer | Tax withholding | 44K | $53.12 | $2.3M | 47K |
| 2025-07-22 | Kelderman Kim | Chief Executive Officer | Exercise or conversion | 48K | $44.33 | $2.1M | 90K |
| 2025-07-15 | Kelderman Kim | Chief Executive Officer | Tax withholding | 33K | $51.42 | $1.7M | 42K |
| 2025-07-15 | Kelderman Kim | Chief Executive Officer | Exercise or conversion | 36K | $44.33 | $1.6M | 75K |
| 2025-06-09 | Herr Amy E. | Director | Sell | 1K | $49.77 | $64K | 2K |
| 2025-06-09 | Herr Amy E. | Director | Exercise or conversion | 1K | $44.33 | $57K | 3K |
| 2025-05-01 | HIGGINS JOHN L | Director | Exercise or conversion | 12K | $21.84 | $262K | 60K |
| 2025-04-03 | Bohnen Shane | SVP - General Counsel | Tax withholding | 747 | $54.86 | $41K | 3K |
| 2025-04-03 | Bohnen Shane | SVP - General Counsel | Exercise or conversion | 2K | $0.00 | $0 | 4K |
| 2025-02-14 | Herr Amy E. | Director | Exercise or conversion | 2K | $44.33 | $88K | 4K |
| 2025-02-14 | Herr Amy E. | Director | Sell | 2K | $65.96 | $123K | 2K |
| 2025-02-03 | Herr Amy E. | Director | Grant | 1K | $0.00 | $0 | 1K |
| 2025-02-01 | Geist William | PRESIDENT, PROTEIN SCIENCES | Exercise or conversion | 3K | $0.00 | $0 | 14K |
| 2025-02-01 | Geist William | PRESIDENT, PROTEIN SCIENCES | Tax withholding | 1K | $73.55 | $82K | 13K |
| 2025-02-01 | McManus Matthew | President - DGS | Exercise or conversion | 5K | $0.00 | $0 | 5K |
| 2025-02-01 | McManus Matthew | President - DGS | Tax withholding | 2K | $73.55 | $121K | 3K |
| 2025-01-27 | Kelderman Kim | Chief Executive Officer | Sell | 2K | $77.95 | $129K | 39K |
| 2025-01-27 | Kelderman Kim | Chief Executive Officer | Exercise or conversion | 13K | $37.70 | $505K | 52K |
| 2025-01-27 | Kelderman Kim | Chief Executive Officer | Sell | 12K | $77.19 | $906K | 41K |
| 2024-11-01 | Hippel James | CFO | Tax withholding | 6K | $75.31 | $488K | 107K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON2 Form 144 notices on file for TECH worth $437K at the prices reported; 0 in the last 90 days worth $0. Latest: JOSHUA MOLHO filed on 2026-05-08 to sell 6,636 shares ($320K) from 2026-05-08.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-05-08 | JOSHUA MOLHODirector | 7K | $320K | 0.004% | 2026-05-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-17 | JOSHUA MOLHODirector | 2K | $117K | 0.001% | 2026-02-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON3 holders report 5% or more of TECH in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 8.1% of the class (12,754,784 shares), filed 2026-08-06 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-06 | 13G/Ano. 1 | FMR LLCparent holding company | 12.8M | 8.1% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 12.8M | 8.1% | 2026-06-30 |
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 11.6M | 7.4% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 13 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2025-11-14 | 13G/Ano. 3 | T. Rowe Price Associates, Inc.investment adviser | 3.4M | 2.2% | 2025-09-30 |
13F holders
Tracked managers holding TECH at their latest 13F. JSON7 of the 30 tracked managers held TECH at their latest 13F, $200.6M in total at quarter-end prices. Millennium Management is the largest at $69.9M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 989K | $69.9M | 0.03% | new |
| Citadel Advisors | 2026-06-30 | 966K | $68.2M | 0.01% | +923K |
| Soros Fund Management | 2026-06-30 | 535K | $37.8M | 0.46% | new |
| D. E. Shaw & Co. | 2026-06-30 | 228K | $16.1M | 0.01% | new |
| Two Sigma Investments | 2026-06-30 | 70K | $4.9M | 0.00% | +4K |
| Bridgewater Associates | 2026-06-30 | 27K | $1.9M | 0.01% | +21K |
| AQR Capital Management | 2026-06-30 | 25K | $1.8M | 0.00% | -43K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q4 FY 2026 (quarter ended 2026-06-30) Bio-Techne reported revenue of $321.2M, up 1.3% from the same quarter a year earlier. In FY 2026 it generated $292.1M of operating cash flow and spent $41.7M on buybacks and $49.9M on dividends.
- Cash
- $264.7M
- Equity
- $2.11B
- Total assets
- $2.59B
- Shares outstanding
- 156,818,238
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q4 FY 2026derived | 2026-06-30 | $321.2M | n/a | n/a | n/a |
| Q3 FY 2026 | 2026-03-31 | $311.4M | $51.0M | 16.4% | 0.32 |
| Q2 FY 2026 | 2025-12-31 | $295.9M | $38.0M | 12.8% | 0.24 |
| Q1 FY 2026 | 2025-09-30 | $286.6M | $38.2M | 13.3% | 0.24 |
| Q4 FY 2025derived | 2025-06-30 | $317.0M | -$17.7M | -5.6% | n/a |
| Q3 FY 2025 | 2025-03-31 | $316.2M | $22.6M | 7.1% | 0.14 |
| Q2 FY 2025 | 2024-12-31 | $297.0M | $34.9M | 11.7% | 0.22 |
| Q1 FY 2025 | 2024-09-30 | $289.5M | $33.6M | 11.6% | 0.21 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2026 | 2026-06-30 | $1.22B | n/a | $292.1M | $28.9M | $41.7M | $49.9M |
| FY 2025 | 2025-06-30 | $1.22B | $73.4M | $287.6M | $31.0M | $275.7M | $50.4M |
| FY 2024 | 2024-06-30 | $1.16B | $168.1M | $299.0M | $62.9M | $80.0M | $50.4M |
| FY 2023 | 2023-06-30 | $1.14B | $285.3M | $254.4M | $38.2M | $19.6M | $50.3M |
| FY 2022 | 2022-06-30 | $1.11B | $272.1M | $325.3M | $44.9M | $160.9M | $50.2M |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-17 from the cover page.
What this page is
Bio-Techne in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Bio-Techne (TECH), SEC CIK 842023, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-22.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-05-08.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-06.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-05-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-28.JSON and CSV
- Company record
- EDGAR filing index for CIK 842023Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
Datasets
Frequently Asked Questions
How much of TECH is sold short?
7,552,208 shares were held short at the 2026-10-15 settlement, 2.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is TECH's daily short volume?
On 2026-10-28, 253,265 of the 720,014 TECH shares reported to FINRA were sold short, 35.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does TECH have fails to deliver?
The SEC's latest file shows 48,379 TECH shares failed to deliver at settlement 2026-09-22. Fails are reported per settlement date and published twice a month with a lag.
Are TECH insiders buying or selling?
No open-market insider trades were reported for TECH in the last 90 days. The most recent filings are listed below. Latest filing: HIGGINS JOHN L (Director) on 2026-09-28.
Have TECH insiders filed to sell?
2 Form 144 notices on file for TECH worth $437K at the prices reported; 0 in the last 90 days worth $0. Latest: JOSHUA MOLHO filed on 2026-05-08 to sell 6,636 shares ($320K) from 2026-05-08.
Who owns 5% or more of TECH?
3 holders report 5% or more of TECH in their latest filing, all on Schedule 13G (passive). The largest reported stake is FMR LLC at 8.1% of the class (12,754,784 shares), filed 2026-08-06 for an event on 2026-06-30.
What did TECH report last quarter?
In Q4 FY 2026 (quarter ended 2026-06-30) Bio-Techne reported revenue of $321.2M, up 1.3% from the same quarter a year earlier. In FY 2026 it generated $292.1M of operating cash flow and spent $41.7M on buybacks and $49.9M on dividends.
Which tracked 13F managers own TECH?
7 of the 30 tracked 13F managers held TECH shares at their latest filing, $200.6M in all. The largest: Izzy Englander's Millennium Management (989K shares, $69.9M), Ken Griffin's Citadel Advisors (966K shares, $68.2M), George Soros's Soros Fund Management (535K shares, $37.8M), D. E. Shaw & Co. (228K shares, $16.1M), Two Sigma Investments (70K shares, $4.9M), Ray Dalio's Bridgewater Associates (27K shares, $1.9M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.